Join Growin Stock Community!

Urogen pharma ltd.URGN.US Overview

US StockHealthcare
(No presentation for URGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

URGN AI Insights

URGN Overall Performance

URGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

URGN Recent Performance

-5.58%

Urogen pharma ltd.

0.05%

Avg of Sector

-0.31%

S&P500

URGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

URGN Key Information

URGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

URGN Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Price of URGN

URGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

URGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.52
PB Ratio
19.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
87.95%
Net Margin
-170.59%
Revenue Growth (YoY)
8.00%
Profit Growth (YoY)
5.23%
3-Year Revenue Growth
19.52%
3-Year Profit Growth
19.80%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.52
PB Ratio
19.27
Price-to-FCF
-
Gross Margin
87.95%
Net Margin
-170.59%
Revenue Growth (YoY)
8.00%
Profit Growth (YoY)
5.23%
3-Year Revenue Growth
19.52%
3-Year Profit Growth
19.80%

  • When is URGN's latest earnings report released?

    The most recent financial report for Urogen pharma ltd. (URGN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating URGN's short-term business performance and financial health. For the latest updates on URGN's earnings releases, visit this page regularly.

  • What is the operating profit of URGN?

    According to the latest financial report, Urogen pharma ltd. (URGN) reported an Operating Profit of -27.39M with an Operating Margin of -99.65% this period, representing a decline of 56.09% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is URGN's revenue growth?

    In the latest financial report, Urogen pharma ltd. (URGN) announced revenue of 27.48M, with a Year-Over-Year growth rate of 9.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does URGN have?

    At the end of the period, Urogen pharma ltd. (URGN) held Total Cash and Cash Equivalents of 91.39M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does URGN go with three margins increasing?

    In the latest report, Urogen pharma ltd. (URGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.1%%, operating margin of -99.65%%, and net margin of -121.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess URGN's profit trajectory and future growth potential.

  • Is URGN's EPS continuing to grow?

    According to the past four quarterly reports, Urogen pharma ltd. (URGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.69. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of URGN?

    Urogen pharma ltd. (URGN)'s Free Cash Flow (FCF) for the period is -42.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 52.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.